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Abstract
While significant progress has been made in understanding the anti-inflammatory
and anti-proliferative effects of the natural diterpenoid component Oridonin on
tumor cells, little is known about its effect on tumor angiogenesis or metastasis and
on the underlying molecular mechanisms. In this study, Oridonin significantly
suppressed human umbilical vascular endothelial cells (HUVECs) proliferation,
migration, and apillary-like structure formation in vitro. Using aortic ring assay and
mouse corneal angiogenesis model, we found that Oridonin inhibited angiogenesis
ex vivo and in vivo. In our animal experiments, Oridonin impeded tumor growth and
metastasis. Immunohistochemistry analysis further revealed that the expression of
CD31 and vWF protein in xenografts was remarkably decreased by the Oridonin.
Furthermore, Oridonin reinforced endothelial cell-cell junction and impaired breast
cancer cell transendothelial migration. Mechanistically, Oridonin not only down-
regulated Jagged2 expression and Notch1 activity but also decreased the
expression of their target genes. In conclusion, our results demonstrated an original
role of Oridonin in inhibiting tumor angiogenesis and propose a mechanism. This
study also provides new evidence supporting the central role of Notch in tumor
angiogenesis and suggests that Oridonin could be a potential drug candidate for
angiogenesis related diseases.
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Introduction
Tumor neoangiogenesis not only supplies nutrients and oxygen to enhance tumor
growth but also, especially, provides the principal route of tumor metastasis which
is the main cause of morbidity and mortality in most cancers [1]. During tumor
metastasis, cancer cells escape from the primary tumor, enter into lymphatic or
blood circulation (intravasation), and then cross the vessel endothelial cell layer to
enter the parenchyma of the target organ. The vasculature endothelial cell layer is
a natural barrier for tumor cell trans-endothelial migration and invasion [2].
Therefore, transendothelial migration (TEM) is a critical step in the metastatic
dissemination of malignant cells from a primary tumor to distant vital organs [3].
Inhibition of TEM may be an effective strategy of suppressing tumor growth and
metastasis.
Among the complex signaling pathways regulating endothelial cell-cell contacts,
which determine the permissibility of TEM, the Notch signaling pathway is critical
[4]. Notch signaling is an evolutionarily conserved pathway that regulates cell fate
decisions during various developmental processes [5]. In mammals, there are five
ligands (Jagged 1, 2, Delta-like 1, 3, 4) and four Notch receptors (Notch 1–4),
which are expressed on the cell surface [5]. Upon Notch ligand binding to a
receptor on an adjacent cell, the intracellular portion of the receptor is cleaved and
translocates into the nucleus, leading to the expression of downstream genes such
as Hes-1 and HESR1.
A growing body of evidence suggests that Notch is an attractive target to block
tumor metastatic progression [6]. Notch mediates communication and interac-
tions between endothelial cells and tumor cells, and promotes tumor angiogenesis
[7, 8, 9]. In the tumor microenvironment, Jagged ligands can be induced by
tumor-associated growth factors such as VEGF [10], followed by activating Notch
expressed in tumor endothelial cells [11]. Curiously, Jagged 2 is the Notch ligand
most significantly correlated with overall and metastasis-free survival of breast
cancer patients [12]. Vascular endothelial cells express the Notch receptors 1, 2
and 3, and Notch signaling is critical to the proper formation of a functional
vasculature [13]. Also, Notch activity was specifically upregulated in the tumor
endothelium, suggesting that interfering with Notch activity may negatively affect
tumor neoangiogenesis. Several Notch inhibitors such as RO4929097 [14] and
MK-0752 [15] have already been used in clinical trials. Therefore, targeting the
Notch pathway in endothelial cells might provide a valid strategy for anti-
angiogenic therapies [16].
Oridonin, an effective diterpenoid component isolated from the medicinal herb
Rabdosia nervosa (Hemsl) [17], has various antibacterial, anti-inflammatory, pro-
apoptotic and anti-tumor activities as well as other pharmacological properties
[18, 19, 20, 21, 22]. Linda C. Meade-Tollin et al. reported Oridonin inhibits
formation of capillary-like networks, which implied Oridonin exhibites anti-
angiogenesis activity [23]. However, the mechanism of Oridonin action on tumor
anigiogenesis remains unknown. In this study, we investigated the mechanism of
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Oridonin in suppressing tumor growth and metastasis through inhibiting tumor
angiogenesis by blocking the Jagged-Notch signaling pathway.
Material and Methods
Chemical, Regents and Animals
Oridonin (Fig. 1A left panel) (purity more than 98%) was purchased from
Shanghai Zhanshu Chemical Technology Co. Ltd in China. VEGF was obtained
from R&D Systems provided by Biological Resources Branch, NCI-Frederick
Cancer Research and Development Center. Matrigel was purchased from BD
Biosciences (San Jose, CA). Notch inhibitor DAPT was purchased from Sigma
(Sigma-Aldrich, Inc., St Louis, Mo, USA).
Sprague Dawley (SD) rats, C57BL/6, BALB/c and nude mice were purchased
from National Rodent Laboratory Animal Resources, Shanghai Branch of China.
Mice were maintained according to the NIH standards established in the
Guidelines for the Care and Use of Experimental Animals, and all of the
experimental protocols were approved by the Animal Investigation Committee of
the Institute of Biomedical Sciences and School of Life Sciences, East China
Normal University.
Cell Culture and Proliferation Assay
HUVECs (ScienCell Research Laboratories, San Diego, CA, USA) were purchased
from Science Research Laboratories and cultured in complete ECM (Sciencell)
supplemented with 5% FBS. HCT116 cells were obtained from the American Type
Tissue Collection (ATCC, Manassas, VA, USA) and maintained in DMEM
supplemented with 10% FBS (Gibco BRL Life Technologies, Eggenstein,
Germany). 4T1 mammary carcinoma cell was purchased from ATCC and
maintained in RPMI-1640 medium supplemented with 10% FBS, 1% Glutamax-1
and 1% penicillin-streptomycin. All cells were maintained at log phase at 37 C˚
with 5% carbon dioxide. Cell proliferation was determined by the Promega
CellTiter 96 (Promega, Madison, WI, USA) nonradioactive cell proliferation assay
according to manufacturer’s instruction [24]. All experiments were performed in
triplicate and repeated at least three times.
Tube Formation and Migration Assay
In vitro angiogenesis was assessed with tube formation and migration assays.
Briefly, 16104 HUVECs were seeded on Matrigel with or without different
concentrations of Oridonin followed by the addition of VEGF (20 ng/ml). After
about 8 hours, photomicrographs were taken with an OLYMPUS inverted
microscope. Tubular structures were quantified by Image-Pro Plus 6.0 software,
and the inhibition percentage was expressed using untreated wells as 100%.
HUVEC migration was determined with a wound healing migration assay and a
modified Boyden chamber assay. Confluent HUVECs were pretreated with
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Fig. 1. Oridonin inhibited angiogenesis in vitro. (A) The chemical structure of Oridonin (Raddosia rubescens) (left panel) and the MTS assay of HUVECs
(right). 56103 HUVECs were seeded in each well of 96-well plates, and incubated with the indicated concentration of Oridonin after cell adhesion. 490 nm
absorbance was measured after 48 hours treatment. (B) Oridonin inhibited VEGF-induced tube formation. 26104 HUVECs per well were seeded in 96-well
plates, and different concentrations of Oridonin were added. Tube like structure length was measured after incubating for 8–10 hours. (C) Oridonin significantly
inhibited VEGF-induced HUVECs wound healing. The cells pretreated with mitomycin C to inhibit proliferation before inducing migration. Dotted lines indicated
the scraped area. Decreased migration was significant at 1 mM,and the difference is highly significant between control and 5 mM of Oridonin. (D) Oridonin
significantly inhibited VEGF-induced Modified Boyden chamber migration. Arrows pointed to the migrated cells. 46104 HUVECs were seeded in the upper
chamber, and after 4 hours migrated cells were stained with crystal violet after fixation with Paraformaldehyde. (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0113830.g001
Oridonin Inhibits Tumor Angiogenesis
PLOS ONE | DOI:10.1371/journal.pone.0113830 December 8, 2014 4 / 20
Mitomycin C for 2 hours before incubating with VEGF (20 ng/ml) and Oridonin
for about 8–12 hours. Migrated cells were photomicrographed and counted
manually. The modified Boyden chamber model (Transwell, 8.0 mm pore size;
Costar) was used as previously described [25]. HUVECs at 80% confluence were
serum-starved for 24 hours. Next, HUVECs (46104) in 100 ml of serum-free
medium were plated in the transwell insert. Then 600 ml of fresh basic ECM
medium containing 10 ng/ml vascular endothelial growth factor (VEGF) and
different concentrations of Oridonin were added into the bottom well. After
4 hours of incubation, cells were washed with PBS to remove the un-invaded cells,
fixed with 4% paraformaldehyde and stained with crystal violet. Migrated cells
were imaged using Olympus IX70 inverted microscope connected to a DXM1200
digital camera and counted manually.
Aortic Ring Spreading Assay
Aortic ring spreading assay was performed as previously described with
modification [26]. 48-well plates were coated with 100 ml of Matrigel per well and
polymerized at 37 C˚ for 30 minutes. Aortic rings harvested from 6 to 8-week-old
Sprague-Dawley rats were plated in the wells and overlaid with 100 ml of Matrigel
for sealing. VEGF (100 ng/ml) in serum-free culture medium, with or without
5 mM Oridonin was added. The medium was changed every two days.
Microvessel-like properties of sprouting structures were observed and photo-
graphed on the 7th day and counted by Image-Pro Plus 6.0 software.
Mouse Corneal Micropocket Assay
Corneal angiogenesis was assessed as described previously [27]. Briefly, in one eye
of 6 to 8-week-old male C57BL/6 mice, corneal micropockets were created using a
modified needle. Micropellet containing 250 ng VEGF was implanted into each
corneal pocket. After injecting 5 mg/kg Oridonin intraperitoneally for seven days,
eyes were imaged under the microscope. The length and clock number of new
blood vessels were surveyed, and the area of neovascularization was calculated
using the formula Area (mm2) 50.263.146VL6CN, where VL is the maximal
vessel length extending from the limbal vasculature toward the pellet, CN is the
clock hours of neovascularization and 1 clock hour equals 30 degrees of arc.
Xenograft Mouse Tumor Model
Male nude mice, 5–6 weeks old, were inoculated subcutaneously in the right flank
with 56106 HCT116 cells suspended in 50 ml PBS. When tumor volume reached
,150 mm3, mice were randomly assigned to the Oridonin treatment group
(n58) or the control (DMSO) group (n58). Oridonin (7.5 mg/kg) was
administered daily by intraperitoneal injection. Tumor volume was determined
using digital vernier caliper measurements and the formula: A6B260.52, where
A is the longest diameter of the tumor and B is the shortest diameter of the tumor.
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Spontaneous Metastasis Model and Hematoxylin & Eosin Staining
The metastasis model was as previously reported [28], orthotopic injections were
performed under anesthesia by using sodium pentobarbital. An incision was made
through the abdominal muscles between 4th and 5th papilla to expose the
mammary fat pat (MFP). 4T1 cells (16105) in 50 ml PBS were injected into the
MFP. Based on the primary tumor size, mice were segregated into groups for the
appropriate treatments. On the day 7, Oridonin was injected intraperitoneally
every two days. Lungs were dissected and fixed in 10% formaldehyde when the
mice were agonal. Paraffin-embedded lungs were cut for H & E staining. Slides
were examined under a light microscopy and pictures were taken at 2006
magnification.
Immunohistochemistry
Paraffin-embedded sections of tumor tissues and lungs were used for
immunohistochemistry staining performed as previously described [29, 30].
Immunohistochemistry analysis was performed on 5-mm sections of formalin-
fixed paraffin-embedded colon tumors derived from mice injected with HCT116
cancer cells. Then 50 serial sections were cut from each tissue, and every 10th
tumor section was stained for expression of the endothelial cell-specific marker
CD31 and Von Willebrand Factor (vWF) by using an anti-CD31 (Lifespan
Biosciences, Inc., Seattle, WA, USA) and anti-vWF polyclonal antibody (Millipore
Corporation, Temecula, California, USA). Lung sections were stained with anti-
CD31 and anti-Pericentrin (Abcam plc. Temecula, California, USA) polyclonal
antibodies. Images were recorded under the Leica DM 4000B photomicroscope
and integrated optical density (mean IOD) of blood vessels in tumor sections was
analyzed using Image-Pro Plus 6.0 software. Angiogenetic vessels consisting of at
least two visible cells in a crosssectional view were scored as positive.
Immunofluorescence
After treating with Oridonin, HUVECs grown on gelatin-coated glass coverslips
were fixed in 4% (w/v) paraformaldehyde and permeabilized with 0.1% Triton-X
100 in PBS. F-actin was visualized by sequential incubation with indicated
antibody overnight at 4 C˚ (Jackson Immunoresearch Laboratories, West Grove,
PA, U.S.A.). Pictures were acquired using a confocal microscope (Leica
Instruments, IN, U.S.A.) controlled by the LAS AF advanced 1.9.0 software
(Diagnostic Instruments).
Transendothelial Migration of Tumor Cells
Tumor cell transendothelial migration was performed as previously described [2].
Approximately 26105 HUVECs were added to matrigel-coated 24-well Transwell
inserts and grown to confluence for 48 hours, with daily replacement of fresh
culture medium. Then, 16105 4T1-GFP cells with different concentration of
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Oridonin were added onto the HUVEC monolayer and incubated for 18–20 hours.
Then the non-migrated cells were removed using a cotton swab. To assay migration,
the migrated cells were photographed and counted manually.
Real-time Quantitative Polymerase Chain Reaction
HUVECs were starved for 12 hours and exposed to various concentrations of
Oridonin for 12 hours and then induced with VEGF (100 ng/ml) for 10 minutes.
Total RNA was isolated from treated HUVECs with Trizol (Invintrogen). 1 mg of
total RNA was high performance reverse transcribed into cDNA in a volume of
20 ml with reverse transcriptase and oligo dT primers (Promega, Madison, USA)
according to the manufacturer’s manual. The cDNA of b-actin served as the
endogenous control. A quantitative fluorogenic SYBR Green (Takara, Otsu, Shiga,
Japan) used for real-time quantification in an ABI prism 7000 sequence detection
system. Primer sequences for Jagged 1, Jagged 2, Dll-1, Notch1, Hes-1 and HESR1
are summarized in the Table 1 [31]. PCR cycles were 5 minutes at 95 C˚, followed
by 40 cycles with an annealing temperature of 56 C˚.
Immunoblot Assay
HUVECs were collected and incubated in lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM
ethylenediaminetetraacetic acid (EDTA), supplemented with protease inhibitors
(10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin A, and 1 mM of 4-
(2-aminoethyl) benzenesulfonyl fluoride) and phosphatase inhibitors (1 mM NaF
and 1 mM Na3VO4) for 30 minutes on ice. Lysates were centrifuged at
12,000 rpm for 20 minutes at 4 C˚. Lysates containing 40 mg of protein were
fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and electro-
transferred to a PVDF membrane. The blocked membranes were then
immunoblotted with primary antibodies (1:1000 dilution) of VE-cadherin, Jagged
2, Notch 1, cleaved Notch 1 (Cell Signaling Tech., Beverly, MA, U.S.A.), Hes-1
(Millipore., Single Oak Drive, Temecula, CA, USA), HESR 1, and b- actin (Sigma,
St. Louis, MO, U.S.A.). The proteins were visualized using enhanced
chemiluminescence by secondary antibody.
Statistical Analysis
Statistical analysis was performed with Microsoft Excel software. The values in
vitro experiments were expressed as means ¡SE. The Student t-test for
independent analysis was applied to evaluate the difference between treatment and
control groups. All experiments were repeated at least three times except animal
experiment. A value of p,0.05 was considered statistically significant.
Oridonin Inhibits Tumor Angiogenesis
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Results
Oridonin Inhibited Endothelia Cell Proliferation
To detect the effect of Oridonin on angiogenesis in vitro, we first examined the
potential anti-proliferation activity of Oridonin on HUVECs with MTS assay.
Result showed that Oridonin significantly inhibits VEGF induced HUVEC
proliferation in a dose-dependent manner, with the IC50 at about 2.5 mM
(Fig. 1A right panel).
Oridonin Inhibited Tube Formation and Migration of HUVECs in
vitro
As tube formation is a critical step in angiogenesis, we investigated whether
Oridonin affected HUVEC angiogenic activity in vitro with tube formation assay.
We found that tubular structures on Matrigel decreased over 90% after treating
with Oridonin (Fig. 1B). Then we examined the effects of Oridonin on migration
of HUVECs in vitro. When incubated with VEGF and Oridonin, HUVEC wound
healing and transwell migration were suppressed in a dose-dependent manner
with the IC50 at 2.5 mM (Fig. 1C and D). Therefore, Oridonin inhibits endothelial
cell proliferation, migration, and tube formation, three activities essential for
angiogenesis.
Oridonin Suppressed Microvessel Formation in the Rat Aortic
Ring ex vivo
In the rat artic ring assay, the effect of Oridonin on the sprouting of vessels from
aortic rings upon VEGF (20 ng/mL) stimulation was examined. After incubation
with 0.1% DMSO and Oridonin for seven days, there were significantly fewer neo-
microvessels from aortic rings in the Oridonin-treated group than those in control
group. 5 mM Oridonin effectively block VEGF-induced microvessel sprouting,
with a reduction of more than 90% (Fig. 2A).
Table 1. Sequences of primers used in Q-PCR reactions.
Genes Forward (5’-3’) Reverse (5’-3’)
Jagged 1 CAACACGGTCCCCATCAAG TACTTCAGAATTGTGTGTCCTTATTTTAGA
Jagged 2 GGCACTCGCTGTATGAAAGGA GCACAACCTCTGGTAACAAACG
Dll-1 GGTCATGGAGTTGTCATTCGTCTA TATCATTTCCTGTGCCAACTCTTTT
Notch 1 CCGCAGTTGTGCTCCTGAA ACCTTGGCGGTCTCGTAGCT
Hes-1 AGCGGGCGCAGATGAC CGTTCATGCACTCGCTGAA
HESR 1 CTTGAGTTCGGCTCTGTGTTCC GATGCCTCTCCGTCTTTTCCT
doi:10.1371/journal.pone.0113830.t001
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Fig. 2. Antiangiogenic activity of Oridonin ex vivo and in vivo. (A) Oridonin inhibited VEGF-induced micro-vessels formation. The right panel shows
quantitation of micro-tube area. (B) The effects of Oridonin in the VEGF-induced mouse corneal vascularization assay. Red arrows indicate the micropellets
that carry VEGF, and the green arrows indicate the neoangiogenic micro-vessels. (C) Quantitation of mouse corneal assay. The Clock number of the
angiogenesis area is on left panel, vessel length of the neoangiogenic vessels (middle panel), and area of angiogenesis vessels (right panel). Here, one
clock number represents a 30 degree arcs, and the area is the product of vessel length and clock number. (**, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0113830.g002
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Oridonin Inhibited VEGF-induced Angiogenesis in vivo in the
Mouse Corneal Neovascularization Model
To further investigate whether Oridonin inhibited VEGF-induced angiogenesis in
vivo, Oridonin was tested in the mouse cornea model. We found that Oridonin
markedly inhibited VEGF-induced neovascularization (Fig. 2B). Quantification
analysis revealed the significant anti-neovascularization effect of Oridonin, with
an 88% reduction of vascularization area (N58, P,0.01) (Fig. 2C right panel). At
the same time, clock number decreased by 66.7% and vessel length by 60% upon
treatment with Oridonin (Fig. 2C left panel and middle panel). These findings
demonstrated that Oridonin was a potent inhibitor of angiogenesis in vivo.
Oridonin Suppressed Tumor Growth and Angiogenesis in Solid
Tumor
Our results above show significant effects of Oridonin on in vitro endothelial cell
parameters relevant to angiogenesis (Figs. 1 and 2) as well as in vivo inhibition of
corneal vascularization (Fig. 2B and C). However, the tumor environment is
complex and characterized by down-regulation of multiple signal transduction
pathways that may impede the efficacy of compounds that function in more
normal settings. Therefore, to investigate the value of Oridonin as an anti-
angiogenic therapeutic compound in tumors, we evaluated the ability of Oridonin
to block tumor growth and angiogenesis in the subcutaneously implanted
HCT116 colorectal carcinoma tumor model [32]. When tumors became palpable,
mice were treated with either Oridonin (7.5 mg/kg per day) or DMSO for 15 days.
We found that tumor size (Fig. 3A, right panel and Fig. 3B-3C, left panels) was
significantly reduced in the Oridonin treated group. The mean tumor weight of
the Oridonin – treated group was also much smaller that of the control group
(Fig. 3B right panel). At the same time, there was no significant difference
between control and Oridonin-treated mouse body weight (Fig. 3C, right panel),
implying the potential for few side-effects of Oridonin at the therapeutic dosage.
Tumor sections stained with anti-CD31 and anti-vWF antibodies revealed that
Oridonin inhibited new blood vessels as well as pruned preexisting tumor vessels
(Fig. 3D). To test the effect of Oridonin on HCT116 tumor cells, additional
analysis with MTS proliferation assay was performed, and results showed that
Oridonin inhibited HCT116 tumor cells proliferayion. However the IC50 of
Oridonin on HCT116 was 10–20 mM (Fig. 3A left panel), which was more than
that on HUVECs (IC50 ,5 mM) (Fig. 1A right panel), suggesting that Oridonin
was more effective in inhibiting proliferation in HUVECs than in HCT116 cells at
the same concentration. These results suggested that Oridonin reduced tumor
growth mainly via inhibiting tumor angiogenesis.
Oridonin Block Tumor Cell Extravasation across the Endothelium
It is well known that malignant tumors depend on neovascularization for their
metastasis [33]. To test whether Oridonin affects tumor metastasis, we performed
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Fig. 3. Oridonin suppressed tumor growth through antiangiogenic activity. (A) The MTS proliferation
assay of HCT116 (left panel) and the representative mice with tumor after treating with DMSO or Oridonin
(right panel). (B) Photographs of DMSO and Oridonin treated group tumors, along with the graph of tumor
weight. (C) The mean tumor size and the body weight of control and Oridonin groups. (D)
Immunohistochemistry of tumor slides stained with antibodies against vWF and CD31; arrows showed new
blood vessels in the tumor, with the statistical results of microvessels on the right. Mean integrated optical
density (mean IOD) of blood vessels accords to the following formula: mean IOD5IOD/area of the tumor
section. (**, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0113830.g003
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tumor metastasis assays, injecting 46105 4T1 breast cancer cells into the
mammary fat pad of BALB/c mice. In all injected BALB/c mice, the primary
tumor burden was high, with no significant difference between treated and
control mouse tumor size, 754 mm3 and 793 mm3, respectively at the 23rd day
(data not shown). To our surprise, metastatic node formation was inhibited in the
Oridonin group (51 nodes in average) compared to the control group (72 nodes
in average); a representative lung from each experimental group was shown in
Fig. 4A. In additional analysis, normal tissue and metastatic nodules in the lung
were obvious after H &E staining, as being sparse or compact, respectively
(Fig. 4B). Metastases comprised 26% of lung area in control mice, but was
significantly reduced in the Oridonin group (12%, n56, p,0.01). Typical areas of
H&E stained lungs in control and Oridonin-treated groups are shown in Fig. 4C.
Individual tumor cells in the Oridonin-treated mice were found inside the blood
vessels (data not shown). To confirm that these cells were tumor cells, we
performed immunofluorescence staining for pericentrin, a centrosomal protein
used to detect neoplastic cells [34]. Breast tumor cells in control lungs with
invasive metastases show a high level of centrosomal abnormalities by
immunofluorescence staining for pericentrin (S1 Figure and Fig. 4D). In
Oridonin–treated mice, tumor cells (green) with centrosomal abnormalities were
only located inside CD31-stained blood vessels (red) (Fig. 4D). No tumor cells
were found outside the vessels. These results may imply that Oridonin inhibits
metastasis formation in vivo by inhibiting the migration/invasion of tumor cells
through the endothelium.
Oridonin Regulated HUVEC Cell-cell contacts and Inhibited Tumor
Cell Transendothelial Migration In Vitro
Cell-cell contact is indispensable during cell motility [35] and actin fibers underlie
early cell-cell contacts [36]. To investigate the mechanism of Oridonin inhibition
of EC migration and tumor cell TEM, we first performed F-Actin and detected the
expression of VE-cadherin. VE-cadherin is crucial for the maintenance and
control of endothelial cell-cell contacts [37]. Results showed that the morphology
and cell junction of HUVECs were changed after treating with Oridonin. There
are more cell-cell connections with Oridonin (Fig. 5A and B). Previous studies
showed that Notch signal pathway contributes to cell-cell contact [38, 39].
Therefore, we treated HUVECs with the Notch inhibitor DAPT and found that
the effects of HUVEC treatment with 10 mM DAPT was similar to that of
Oridonin (Fig. 5A and B). These results suggested that the molecular mechanism
of Oridonin biological effects in HUVECs may involve Notch pathway signaling.
Tumor cell transendothelial migration is a crucial step in both the intravasation
of cells from primary tumors into the vasculature and in extravasation of
circulating tumor cells into suitable secondary sites leading to tumor metastatic
colonization [40]. To further study whether Oridonin affects TEM, we measured
the transendothelial migration of 4T1 breast cancer cells. In order to exclude the
confounding effects of differing HUVEC densities, the monolayer in each
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Fig. 4. Oridonin inhibited tumor metastasis through blocking tumor cell trans-endothelium. (A) Right
panel, representative lungs of mice (n56 per group) from the metastasis model. Arrows indicate the
metastasis nodes. Quantitation is shown in the right panel. (B) The photographs of haematoxylin and eosin
(H&E) staining of control (DMSO) or treatment (Oridonin) group lung tissues are shown. The graph shows a
comparison of metastatic area in control and Oridonin treated group (n56). (C) The magnified images of H&E
staining of lungs in Fig. 4B. ‘‘T’’ indicates the metastatic tumor nodes in the lung. (D) Typical images of lungs in
Oridonin-treated breast cancer metastasis. As showed by immunofluorescence double staining using anti-
CD31 (red) and anti-pericentrin (green) antibodies, all breast cancer cells are inside of blood vessels. The
asterisk shows red blood endothelial cells. (**, P,0.01).
doi:10.1371/journal.pone.0113830.g004
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Fig. 5. Oridonin increased the cell-cell connections of HUVECs and decreased tumor cell transendothelial invason. (A) HUVEC morphology and
cell-cell contacts by immunofluorescence assay. Arrows show the contact of endothelial cell edge with different concentrations of Oridonin. (B) HUVECs
were treated with Oridonin or DAPT for 24 hours. Cells were fixed and stained with VE-cadherin. Photographs were obtained through a confocal microscope
(left panel). HUVECs were treated with Oridonin or DAPT for 24 hours, and cells were harvested. VE-cadherin expression was examined by western blot
analysis (right panel). (C) Transendothelial migration of 4T1 breast tumor cells with FBS or VEGF stimulation of HUVECs. 26105 HUVECs were grown to
confluency for 48 hours on the Transwell membrane. HUVECs were treated with FBS or VEGF (20 ng/ml) for 18 hours. 16105 4T1-GFP cells serum-
starved overnight were added on the monolayer of HUVECs and incubated for 6 hours. After migrated cells were fixed and stained, the photographs were
acquired. (D) The represent photographs of Fig. 5C. (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0113830.g005
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chamber was confirmed to be confluent by visual inspection for each experiment.
As showed in Fig. 5C and D, 4T1 tumor cell transendothelial migration could be
enhanced by FBS or VEGF and Oridonin decreased VEGF-induced migration
more effectively than FBS-induced trans-HUVEC migration, with an IC50 of less
than 1 mM. These data showed that Oridonin inhibits an important step in breast
cancer cell transendothelial migration in vivo.
Oridonin Blocked the Jagged-Notch Signaling Pathway in
Endothelial Cells
One published signaling cascade mediating VEGF signaling is the Notch pathway.
We were interested to determine whether Oridonin could affect Notch signaling
in endothelial cells. First, we verified inhibition of Notch signaling in HUVECs
using a known Notch inhibitor, DAPT. To examine the effects and concentration-
dependence of DAPT on Notch signaling in HUVECs, we performed Q-PCR and
western blot assays. 20 mM DAPT suppressed the mRNA expression of Dll-1,
Jagged2, Notch1 and Hes-1, which are involved in the Notch pathway (Fig. 6A left
panel). At the same time, DAPT inhibited VEGF-induced Notch activity (Fig. 6A
right panel). Thereafter we used 20 mM DAPT as the positive control in the
gsubsequent assays to measure Oridonin effects on Notch signaling. As expected,
Oridonin remarkably inhibited key ligands, receptor and downstream genes and
protein expression involved in Jagged-Notch Signaling Pathway (Fig. 6B and C).
In particular, note the inhibition of both Jagged2 ligand and VEGF-stimulated
Notch activation at 10 mM Oridonin, suggesting potency of VEGF/Notch
inhibition by Oridonin at concentrations relevant to effects on endothelial cell
functions in vitro. Therefore, Oridonin inhibition of angiogenesis may occur
through blockage of VEGF stimulation of Jagged2 and Notch activation.
Discussion
Angiogenesis is required for tumor growth and metastasis [25]. Identification of
novel angiogenesis inhibitor will benefit drug discovery for treating angiogenic
diseases, such as tumor. Here, we found that Oridonin not only inhibited
angiogenesis in the mouse cornea assay, the golden standard for angiogenesis, but
also suppressed rat artery ring sprouting. In addition, Oridonin inhibited tube
formation which was consistent with a previous result that Oridonin could inhibit
capillary-like networks formation of human dermal microvascular endothelial
cells [23].
Over 90% of deaths from solid tumors are attributable to tumor metastasis
[41]. Cancer metastasis is a multistep process involving many types of cell-cell
interactions. In the tumor metastatic cascade, tumor cells initially attach to
vascular endothelium and intravasate, followed by circulation and extravasation
from the blood stream. To form metastases, migrating tumor cells must overcome
the endothelial barrier [42] which is accompanied by drastic changes in
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cytoskeletal organization in neighboring endothelial cells [43]. Therefore,
transendothelial migration of tumor cells is a crucial step of metastasis and
inhibitors of transendothelial migration may be an attractive way of blocking
metastasis. Here, we found that Oridonin promoted HUVECs cell-cell connec-
tions (Fig. 5A), which may have prevented tumor cells from crossing the
endothelial cell layer. At the same time, data presented here provided evidence
Fig. 6. Notch pathway was regulated in Oridonin in HUVECs. (A) DAPT blocked Notch gene transcription
and Notch activity. (B) and (C) Oridonin remarkably inhibited expression of key ligands, receptors and
downstream genes (Fig. 6B, Q-PCR) and proteins (Fig. 6C, Western blot) involved in the Jagged-Notch
Signaling Pathway. (D) Schematic diagram of Oridonin inhibiting tumor growth and tumor metastasis by
regulating the Jagged-Notch signaling pathway in HUVECs.
doi:10.1371/journal.pone.0113830.g006
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that Oridonin more significantly inhibited VEGF-induced transendothelial
migration than that of FBS-induced in breast cancer cell (Fig. 5B), implying that
Oridonin has potential specificity for a downstream target of VEGF signaling.
These results, together with the effects of tumor metastasis and growth inhibition,
suggested that inhibition of transendothelial migration of tumor cells is an
important aspect of blocking breast tumor metastasis by Oridonin.
Among the molecular mechanisms involved in tumor angiogenesis and
metastasis, accumulating evidence suggests that Notch is a key regulator of tumor
angiogenesis and metastasis [6, 44, 45]. Disruption of Notch has been implicated
in multiple tumor types [46]. In breast cancer, evidence from in vitro experiments,
mouse models and human tumor samples indicated that Notch plays a
predominantly oncogenic role [46], suggesting the importance of Notch signaling
pathways during tumor development. VEGF and Notch are interacting signaling
pathways in tumor angiogenesis [47]. It is well established that the VEGF acts as a
potent activating stimulus for angiogenesis, whereas Notch appears to help guide
cell fate decisions that appropriately shape this activation. These reports suggest
that VEGF and Notch may be valid therapeutic targets in cancer [48]. In the
present study, we demonstrated that Oridonin inhibited the expression of
Jagged2, Notch, and their downstream genes (Fig. 6B), similar to the effect of the
Notch inhibitor DAPT (Fig. 6A). Furthermore, we found that Oridonin down-
regulated the activity of Notch (Fig. 6C). These results suggested that the above
biological functions of Oridonin in inhibiting tumor angiogenesis and metastasis
was accomplished through blocking the Jagged-Notch pathway.
In conclusion, our results indicate that Oridonin inhibited tumor growth and
metastasis via suppressing tumor angiogenesis by blocking the VEGF induced
Jagged-Notch signal pathway. Oridonin may be an effective anti-tumor candidate
therapeutic by regulating Jagged-Notch activity in cancer therapy.
Supporting Information
S1 Figure. Oridonin inhibited tumor metastasis through blocking tumor cell
trans-endothelium. (A) Typical images of lungs in control group. No breast
cancer cells are inside of blood vessels.
doi:10.1371/journal.pone.0113830.s001 (TIF)
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